Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19162 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Eleonora Calabretta und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. Hauptthemen laut MEDLINE: Hodgkin Disease, Circulating Tumor DNA. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro.
Abstract (Originalsprache)
Reliable biomarkers for early identification of treatment failure in relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL) are lacking. Circulating tumour DNA (ctDNA) profiling has emerged as a powerful predictive and prognostic tool in several haemopoietic and non‐haemopoietic malignancies and may guide rational treatment choices in r/r cHL. To assess the predictive and prognostic value of ctDNA, we performed a retrospective analysis on 55 r/r cHL patients treated with the bendamustine, gemcitabine and vinorelbine (BEGEV) regimen and additionally evaluated the potential utility of integrating ctDNA with interim [ 18 F]‐FDG positron emission tomography (iPET). Baseline ctDNA genotyping in r/r cHL mirrored gene mutations and pathways involved in newly diagnosed cHL. We found that baseline ctDNA quantification and serial ctDNA monitoring have prognostic value in r/r cHL receiving salvage chemotherapy. Lastly, integrating ctDNA quantification with iPET evaluation may improve the early identification of patients at high risk of failing standard salvage therapy, who may benefit from an early switch to immunotherapeutic agents. Collectively, our results support the implementation of non‐invasive methods to detect minimal residual disease in recurrent cHL and justify its prospective evaluation in appropriately designed clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
- Department of Oncology and Hematology, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
- Nuclear Medicine, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
- Laboratory of Experimental Hematology, Institute of Oncology Research, Università della Svizzera Italiana, Bellinzona, Switzerland.
- Clinic of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
ORCID-Profile: Eleonora Calabretta, Carmelo Carlo-Stella
Förderung
- Associazione Italiana per la Ricerca sul Cancro
Zitieren
APA
Calabretta, E., di Trani, M., Corrado, F., Sollini, M., Cristaldi, V., Marino, F., Terzi di Bergamo, L., Bruscaggin, A., Pirosa, M. C., Bramanti, S., Chiti, A., Rossi, D., & Carlo-Stella, C. (2024). Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma. British Journal of Haematology. https://doi.org/10.1111/bjh.19162
Vancouver
Calabretta E, di Trani M, Corrado F, Sollini M, Cristaldi V, Marino F, et al. Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma. British Journal of Haematology. 2024. doi:10.1111/bjh.19162
BibTeX
@article{Calabretta2024,
author = {Calabretta, Eleonora and di Trani, Martina and Corrado, Francesco and Sollini, Martina and Cristaldi, Vanessa and Marino, Fabrizio and Terzi di Bergamo, Lodovico and Bruscaggin, Alessio and Pirosa, Maria Cristina and Bramanti, Stefania and Chiti, Arturo and Rossi, Davide and Carlo-Stella, Carmelo},
title = {Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19162}
}
EUVIMED